Can abacavir (nucleoside reverse transcriptase inhibitor) or lamivudine (nucleoside reverse transcriptase inhibitor) change urine color?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Urine Color Changes with Abacavir and Lamivudine

Neither abacavir nor lamivudine are known to cause changes in urine color based on available clinical evidence and guidelines.

Evidence Review

The provided guidelines and research studies extensively document the pharmacokinetics, adverse effects, and clinical management of both abacavir and lamivudine, but none mention urine discoloration as a recognized side effect 1.

Abacavir Safety Profile

  • The most commonly reported adverse events with abacavir include nausea, vomiting, malaise, fatigue, headache, diarrhea, sleep disorders, and rash 2, 3.
  • The major safety concern with abacavir is hypersensitivity reaction (occurring in 3-5% of patients), which typically presents with fever, rash, and multiorgan involvement—not urine color changes 2, 3.
  • Abacavir is extensively metabolized by the liver with less than 2% excreted unchanged in urine, making urine discoloration pharmacologically unlikely 4.

Lamivudine Safety Profile

  • Lamivudine requires dose adjustment in renal impairment (CrCl <50 mL/min), but urine color changes are not documented as part of its adverse effect profile 1, 5.
  • The drug is primarily renally excreted, but this does not translate to visible urine discoloration 1.

Clinical Considerations

  • If a patient on abacavir or lamivudine reports urine color changes, investigate alternative causes including other medications, dietary factors, dehydration, or underlying pathology 6.
  • Both drugs can affect renal function (particularly when combined with tenofovir), which may manifest as proteinuria or glycosuria—but not as visible urine color changes 1.
  • Urinalysis abnormalities such as proteinuria or glycosuria from proximal tubular dysfunction (especially with concurrent tenofovir use) do not cause visible color changes but require monitoring 1.

Important Caveats

  • While these medications do not cause urine discoloration, patients may be taking other antiretrovirals or medications that could affect urine color 6.
  • Atazanavir (a protease inhibitor sometimes used with these NRTIs) can cause hyperbilirubinemia leading to dark urine, but this is unrelated to abacavir or lamivudine themselves 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Abacavir.

Drugs, 1998

Research

A review of the pharmacokinetics of abacavir.

Clinical pharmacokinetics, 2008

Guideline

Dosing Recommendations for Patients with Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Abnormal urine color.

Southern medical journal, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.